化学性质:
规格 | 10mM (in 1mL DMSO) 5mg 10mg 50mg |
CAS | 173529-46-9 |
别名 |
|
化学名 | N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-1-ium-4-yl)ethenyl]phenyl]acetamide |
分子式 | C22H20N2O5S |
分子量 | 424.47 |
溶解度 | ≥ 21.2mg/mL in DMSO |
储存条件 | Store at -20°C |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice |
产品描述:
IC50: HMN-176 showed potent cytotoxic activity against several tumor cell lines with an average IC50 of 118 nmol/L
The polo-like kinases (PLK) are a group of highly conserved serine/threonine kinases that serve as regulatory enzymes for mitotic events. HMN-214 is an oral prodrug of HMN-176, a stilbene derivative that interferes with the subcellular spatial location of polo-like kinase-1, a serine/threonine kinase that regulates critical mitotic events.
In vitro: HMN-176 showed potent cytotoxicity, with a mean IC50 of 118 nM. The cytotoxic effecacy of HNM-176 was superior to that of ADM, VP-16 and CDDP, but inferior to that of taxol and VCR. HMN-176 showed less vaiance in log(IC50) than did the reference agents. In addition, judging by its low resistance indices, HMN-176 was more cytotoxic toward the drug-resistant phenotypes of tumor cells than were the other agents tested [1].
In vivo: PK studies showed that HNM-214 was an acceptable oral prodrug of HMN-176. In the in vivo analysis of the schedule-dependency of HMN-214, the repeated administration for over 5 days elicited potent antitumor activity, as expected from the exposure-dependency of the cytotoxicity of HMN-176 and from the cytometric studies. The antitumor activity of HMN-214 against human tumor xenografts was equal or superior to that of clinically avaiable agents, including cis-platinum, adriamycin, vincristine and UFT without severe toxicity such as neurotoxicity [1].
Clinical trial: A phase I pharmacokinetic study indicated that there was no accumulation of HMN-176, the metabolite of HMN-214, with repeated dosing. Seven of 29 patients had stable disease, including 6-month stable disease in a heavily pretreated breast cancer patient. A transient carcinoembryonic antigen decline in a patient with colorectal cancer was noted [2].
特别提醒:
1. 本产品仅供科研使用。请勿用于医药、临床诊断或治疗,食品及化妆品等用途。请勿存放于普通住宅区。
2. 为了您的安全和健康,请穿好实验服并佩戴一次性手套和口罩操作。
标签:HMN-214
联系人:高小姐
手 机:13585831301
Q Q:3004967995
座 机:021-59541103
传 真:021-60443211
地 址:上海嘉定区嘉罗公路1661